Detalhe da pesquisa
1.
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
N Engl J Med
; 388(25): 2338-2348, 2023 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37342922
2.
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Cancer
; 129(14): 2179-2191, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021929
3.
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood
; 137(19): 2634-2645, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33211842
4.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study.
Haematologica
; 2023 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646659
5.
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Haematologica
; 108(1): 150-160, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443559
6.
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Haematologica
; 108(7): 1900-1908, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779595
7.
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 790-800, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989558
8.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
9.
Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
Br J Haematol
; 195(5): 757-763, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34581433
10.
Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.
Biol Blood Marrow Transplant
; 26(11): 2082-2088, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32745575
11.
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.
Biol Blood Marrow Transplant
; 26(10): 1930-1936, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32649981
12.
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
Biol Blood Marrow Transplant
; 26(3): 472-479, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31669399
13.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Biol Blood Marrow Transplant
; 26(11): 2139-2146, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32781289
14.
Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Cancer
; 126(23): 5077-5087, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32965680
15.
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: young HLA-matched unrelated or haploidentical donor?
Haematologica
; 105(2): 407-413, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101756
16.
Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy.
Biol Blood Marrow Transplant
; 25(11): 2211-2216, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31247313
17.
Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
Biol Blood Marrow Transplant
; 25(10): 2054-2060, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31173900
18.
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(3): 606-612, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30244109
19.
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Biol Blood Marrow Transplant
; 25(4): 683-688, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30579965
20.
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Biol Blood Marrow Transplant
; 25(1): 73-85, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30153491